DEC 18, 2019 8:32 AM PST

Germs don't stand a chance with new AI-powered diagnostic platform

WRITTEN BY: Tara Fernandez

We are steadily losing our edge in the war against infectious bacteria. A huge surge in antibiotic resistance is threatening healthcare and agricultural industries. Annually, 2.8 million people became infected with antibiotic-resistant microbes in the U.S. alone.

Since penicillin, our arsenal of antimicrobial drugs has grown, only to be swiftly overpowered by selective pressure and DNA mutations that give bacteria the upper hand.

In 2015, for instance, the antibiotic Ceftazidime-avibactam was approved by the Food and Drug Administration to treat hospital-acquired pneumonia and other multi-drug resistant infections. Featured as a reserve on the World Health Organization’s List of Essential Medicines, healthcare experts were hopeful that this medication would function as a last resort to resist superbugs.

Disastrously, in the same year of its release, the gut bacteria Klebsiella pneumoniae was found to have acquired resistance, making it a potentially deadly hospital-acquired infection threat.

On the verge of a global medical crisis, Niamh O’Hara, Co-founder and CEO of the biotech start-up, Biotia, saw an opportunity. Using next-generation DNA sequencing and software powered by artificial intelligence, O’Hara and colleagues at Weill Cornell Medicine and Cornell Tech have developed a robust digital platform for diagnosing and controlling microbial infections.

 

 

As O’Hara explains, the method most hospitals use to identify pathogens dates back to the 1800s: a process called culturing. Here, bacteria from patient samples are provided with nutrients and optimal growth conditions and allowed to multiply so that a microbiologist can establish their origin. This low-tech system is prone to failure and provides only limited information regarding how successfully the infection can be treated with antibiotics.

Biotia’s system, which recently raised $2.4 million in investment funding, genetically profiles bacteria with unparalleled precision and uses powerful computing systems to predict the likelihood of developing resistance. The artificial intelligence-driven software, known as Chelsea™, scans a genetic database of over 16,000 bacteria, viruses, fungi, and parasites, providing a complete report on exactly what the offending pathogen is and predicts its drug resistance.

Working closely with hospitals during this developmental phase, Biotia’s founders envision a future where healthcare providers can provide rapid, targeted, life-saving treatments and where hospital-acquired infections become a thing of the past.

 

Sources: Cornell Tech, Biotia.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
SEP 08, 2019
Health & Medicine
SEP 08, 2019
Acute Flaccid Myelitis and Its Association With Enterovirus D68
Acute flaccid myelitis (AFM), a polio-like infection, caught the attention of physicians in the U.S. during late summer and early fall in 2014. The outbrea...
OCT 09, 2019
Neuroscience
OCT 09, 2019
Elderly Depression Remains Consistant As Antidepressant Use Doubles
  A new study from the University of East Anglia finds that despite a 2-fold increase in antidepressant use, depression among individuals 65 and older...
OCT 18, 2019
Clinical & Molecular DX
OCT 18, 2019
AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia
To support the validation and verification of new assays in oncology testing, Thermo Fisher Scientific with AcroMetrix control products provides innov...
NOV 14, 2019
Chemistry & Physics
NOV 14, 2019
Examining the Squirrelly Ones: Wearable MEG Scanner that Suits Pediatric Patients
In a recent study, a joint research team at the University of Nottingham, University of Oxford, and University College London successfully tested a ne...
DEC 11, 2019
Clinical & Molecular DX
DEC 11, 2019
New 3-in-1 organ in a dish set to elevate research and diagnostics
In trying to understand complex phenomena in the human body, researchers usually have to turn to oversimplified biological models. Amongst the easiest to u...
JAN 14, 2020
Clinical & Molecular DX
JAN 14, 2020
Can I eat this donut? A quick test for celiac disease.
Genetic testing revealed that our ancestors have been eating wheat, rye, spelt and barley for over 8,000 years. Today, gluten, a protein found within these...
Loading Comments...